Jan 9, 2020 5:00 pm EST Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2019 Performance Results, Delivering 29% DecisionDx-Melanoma Test Report Volume Growth in 2019
Dec 30, 2019 7:00 am EST Castle Biosciences Announces Level of Evidence Review on DecisionDx-Melanoma Published in Latest Issue of American Journal of Clinical Dermatology
Dec 3, 2019 5:00 pm EST Castle Biosciences Announces Time Change for Presentation at the Evercore ISI Second Annual HealthCONx
Nov 25, 2019 7:00 am EST Castle Biosciences Presents Expanded Data Supporting Use of DecisionDx-Melanoma Test to Inform Sentinel Lymph Node Biopsy Recommendations
Oct 31, 2019 7:00 am EDT Study Results Confirm Newly Developed Nomogram Using Castle Biosciences’ DecisionDx-Melanoma Test Improves Assessment of Melanoma Patient Risk
Oct 29, 2019 7:00 am EDT Castle Biosciences Presents Clinical Validation Study for its Cutaneous Squamous Cell Carcinoma Prognostic Test at the American Society for Dermatologic Surgery (ASDS) 2019 Annual Meeting
Oct 28, 2019 7:00 am EDT Castle Biosciences Presents Second Study Confirming Ability of DecisionDx-Melanoma to Inform Sentinel Lymph Node Biopsy Decisions at the 8th International Congress on Cancer Metastasis
